Metabolic shift: Scientists Unlock Secrets of Immune Cell Activation, Paving way for New Therapies
A groundbreaking study from St. Jude Children’s Research Hospital has revealed a critical link between cellular metabolism and teh activation of regulatory T cells (Tregs), the immune system’s crucial controllers. Published today in Science Immunology, the research details how the interplay between mitochondria and lysosomes dictates the behavior of these cells, offering potential new avenues for treating autoimmune diseases, inflammatory disorders, and even improving cancer immunotherapy.
Regulatory T cells are essential for maintaining immune balance. When the immune system responds to a threat, inflammation arises to combat the issue. Tregs step in to ensure this inflammation is properly controlled, returning tissues to a normal state once the danger has passed. Their importance is underscored by the anticipated recognition of their finding with the 2025 Nobel Prize in Physiology or Medicine.
Dysfunctional Tregs can led to uncontrolled inflammation, resulting in tissue damage and autoimmune disorders where the immune system mistakenly attacks the body’s own tissues. despite their vital role, the precise molecular mechanisms governing Treg activation have remained elusive – until now.
“We discovered how regulatory T cells are activated and become more immunosuppressive during inflammation,” explained a senior researcher. “By defining how cellular metabolism rewires regulatory T cells through different states of activation, including their return to a resting state, we have provided a roadmap
for understanding how to manipulate these cells to treat disease.” The study found that Tregs rely heavily on mitochondrial activity to fuel their immunosuppressive functions. This suggests a direct correlation between mitochondrial activity and Treg activation during inflammation.
Interestingly, when the scientists disabled the Opa1 gene, crucial for maintaining mitochondrial cristae structure, they found that cells attempted to compensate by increasing the abundance of lysosomes. These cellular “recycling systems” break down waste materials and generate building blocks for energy production. However, Tregs lacking Opa1 still struggled to produce sufficient energy and maintain their immunosuppressive function.
Further experimentation revealed that deleting Flcn,a gene that regulates lysosome activity,also impaired Treg function. Deleting either Flcn or Opa1 altered the activity of TFEB, a protein controlling lysosome-associated gene expression in response to energy stress. This disruption also enhanced AMPK signaling, another key pathway, demonstrating a clear dialog network between the two organelles.
“We are the first to dissect this inter-organelle signaling between mitochondria and lysosomes in regulatory T cells,” stated a researcher. “It shows that these metabolic signaling pathways control discrete activation states, and ultimately, how well these cells perform their immunosuppressive functions.”
Implications for Cancer Immunotherapy and Beyond
A surprising finding emerged regarding the role of Flcn. Without Flcn, Tregs were unable to migrate to non-lymphoid tissues like the lung and liver – locations where they typically exert their suppressive effects. These same programs are also crucial for Treg function within tumors,where they can hinder the activity of anti-cancer immune cells.
Testing this hypothesis, the researchers found that deleting Flcn in Tregs enhanced the immune response against tumors, leading to a reduction in tumor size. Importantly,Flcn deletion also reduced the accumulation of CD8+ T cells that had become “exhausted,” a common obstacle to effective immunotherapy. These results suggest that modulating Flcn activity in Tregs could unlock new strategies to boost anti-tumor immunity and improve cancer treatment outcomes.
“We’ve taken the first unbiased look at the metabolic mechanisms of how regulatory T cells become activated during inflammation,” saeid a senior official. “We now have a better understanding of how organelles direct resting versus highly activated regulatory T-cell states in inflammation and tissues, providing new insights that will help improve treatments for autoimmune disorders and cancer.”
